Wilson Asset Management International PTY Ltd. Takes $13.03 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Wilson Asset Management International PTY Ltd. acquired a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 31,034 shares of the company's stock, valued at approximately $13,033,000. IDEXX Laboratories makes up 3.5% of Wilson Asset Management International PTY Ltd.'s investment portfolio, making the stock its 16th biggest position.

Other institutional investors and hedge funds have also recently modified their holdings of the company. MorganRosel Wealth Management LLC bought a new stake in shares of IDEXX Laboratories during the first quarter valued at approximately $26,000. Hurley Capital LLC purchased a new position in IDEXX Laboratories during the fourth quarter valued at $29,000. Rialto Wealth Management LLC bought a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $30,000. Colonial Trust Co SC grew its position in shares of IDEXX Laboratories by 84.8% in the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company's stock worth $35,000 after buying an additional 39 shares during the period. Finally, Itau Unibanco Holding S.A. grew its position in shares of IDEXX Laboratories by 540.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock worth $40,000 after buying an additional 81 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Up 0.0%

Shares of IDXX traded up $0.06 on Wednesday, hitting $542.71. 380,154 shares of the stock traded hands, compared to its average volume of 644,790. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $548.10. The company has a market capitalization of $43.64 billion, a PE ratio of 50.16, a P/E/G ratio of 3.92 and a beta of 1.54. The business has a 50 day simple moving average of $504.03 and a 200 day simple moving average of $452.31. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.81 and a current ratio of 1.16.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The business had revenue of $998.43 million during the quarter, compared to analyst estimates of $998.25 million. During the same quarter last year, the company earned $2.71 EPS. The company's quarterly revenue was up 3.6% compared to the same quarter last year. As a group, equities analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Buying and Selling

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of the company's stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total transaction of $645,548.40. Following the transaction, the director owned 1,801 shares in the company, valued at approximately $922,724.34. This represents a 41.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.98% of the company's stock.

Analyst Ratings Changes

Several research firms recently commented on IDXX. Morgan Stanley boosted their price objective on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research note on Monday, May 5th. Leerink Partners lifted their target price on shares of IDEXX Laboratories from $515.00 to $580.00 and gave the company an "outperform" rating in a report on Wednesday, June 11th. Stifel Nicolaus upped their price target on IDEXX Laboratories from $510.00 to $540.00 and gave the stock a "hold" rating in a research note on Wednesday. Jefferies Financial Group initiated coverage on IDEXX Laboratories in a research report on Tuesday. They set a "buy" rating and a $625.00 price objective for the company. Finally, Wall Street Zen cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $558.11.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.